In the BioHarmony Drug Report Database

"Preview" Icon

Ziv-aflibercept

Eylea, Zaltrap (aflibercept) is a protein pharmaceutical. Aflibercept was first approved as Eylea on 2011-11-18. It is used to treat diabetic retinopathy and macular edema in the USA. It has been approved in Europe to treat colorectal neoplasms, diabetes complications, macular edema, and wet macular degeneration. The pharmaceutical is active against vascular endothelial growth factor A.

 

Trade Name

 

Eylea, Zaltrap
 

Common Name

 

aflibercept
 

ChEMBL ID

 

CHEMBL1742982
 

Indication

 

colorectal neoplasms, diabetes complications, diabetic retinopathy, macular edema, wet macular degeneration
 

Drug Class

 

Receptor molecules, native or modified: vascular endothelial growth factor (VEGF) receptors

Image (chem structure or protein)

Ziv-aflibercept structure rendering